Screener
Halozyme Therapeutics HALO Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The source filing: Halozyme Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001159036-26-000104
| Line item | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|
| Proceeds from sales and maturities of marketable securities | 62,269 | 239,278 |
| Proceeds from working capital adjustments on acquisition | 710 | — |
| Purchases of property and equipment | (7,914) | (2,513) |
| Net cash used in investing activities | (65,540) | (5,634) |
| Financing activities | ||
| Repurchase of common stock | (332,729) | (303,489) |
| Proceeds from issuance of common stock under equity incentive plans, net of taxes paid related to net share settlement | 4,865 | 1,202 |
| Net cash used in financing activities | (327,864) | (302,287) |
Item 1. Financial Statements
FAQ
- What is Halozyme Therapeutics's investing cash flow?
- Halozyme Therapeutics (HALO) reported investing cash flow of -$62.66M in Q2 2026.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.
Ask your AI about Halozyme Therapeutics's investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude